Skip to main content

CD58 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Be the first to review this product! Submit a review

Images

Next Generation Sequencing - Human CD58 knockout Raji cell line (AB290422), expandable thumbnail

Key facts

Cell type
Raji
Species or organism
Human
Tissue
Lymphatic
Form
Liquid
Knockout validation
Next Generation Sequencing

Alternative names

Recommended products

CD58 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Key facts

Cell type
Raji
Form
Liquid
Disease
Lymphoma
Concentration
Loading...

Properties

Gene name
CD58
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Suspension
Gender
Male

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water for bath approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 4x105 - 5x105 cells/mL(for initial passages it is recomended to culture the cells in the higher range of recomended seeding density). Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 4x105 cells/mL is recommended.
  • A maximum of 3x106 viable cells/mL is obtainable.
Culture medium
RPMI + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type Raji cell line (ab290717). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

CD58 also known as lymphocyte function-associated antigen 3 (LFA-3) is a glycoprotein with a molecular mass of approximately 60 kDa. It is present on the surface of various cell types including antigen-presenting cells epithelial cells and some other leukocytes. This protein serves as a ligand for CD2 which is expressed on T cells and natural killer cells. Through its interaction with CD2 CD58 mediates cell adhesion and plays a role in immunological synapse formation which is essential for effective immune responses.

Biological function summary

Lymphocyte function-associated antigen 3 acts as a significant participant in the immune system. It plays a role in T cell activation and facilitates interactions between T cells and antigen-presenting cells. CD58 forms part of a complex network of cell surface proteins that enhances immune surveillance and response. Its role highlights its importance in adaptive immunity by promoting cell-to-cell communication and activation.

Pathways

CD58 participates in the cell adhesion pathways. It interacts closely with CD2 which is involved in the activation and signaling of T cells. Through this interaction CD58 plays roles in pathways like T cell receptor signaling and immune response. It enhances cell-cell adhesion helping T cells maintain their position during immune surveillance and activation.

Associated diseases and disorders

CD58 relates to conditions such as autoimmune diseases and certain cancers. In autoimmune disorders aberrant expression or function of CD58 may contribute to inappropriate immune activation leading to tissue damage. In cancer CD58 alterations can affect tumor immune evasion influencing how the immune system recognizes and attacks cancer cells. In multiple sclerosis an autoimmune disease the interaction between CD58 and CD2 has been studied providing insights into its role in disease mechanisms.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Next Generation Sequencing - Human CD58 knockout Raji cell line (ab290422), expandable thumbnail

    Next Generation Sequencing - Human CD58 knockout Raji cell line (ab290422)

    107 bp deletion in exon 3, CCDS888.1

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com